HANSON GREGORY P 4
4 · MABVAX THERAPEUTICS HOLDINGS, INC. · Filed Aug 2, 2017
Insider Transaction Report
Form 4
HANSON GREGORY P
Chief Financial Officer
Transactions
- Sale
Class B Warrant
2017-05-19−3,119→ 0 totalExercise: $6.29→ Common Stock (3,119 underlying) - Purchase
Common Stock
2017-05-19+4,842→ 38,334 total - Purchase
Common Stock
2017-05-19$1.75/sh+4,286$7,501→ 33,492 total - Sale
Class A Warrant
2017-05-19−3,119→ 0 totalExercise: $5.55→ Common Stock (3,119 underlying)
Footnotes (3)
- [F1]These shares were received in exchange for making an investment under the terms of the Company's May 2017 public offering equal to 50% of investment made in the Company's August 2016 public offering, and for the cancellation of (i) warrants to purchase 3,119 shares of the Company's common stock at a price per share of $5.55 issued to the Reporting Person on August 17, 2016 and (ii) warrants to purchase 3,119 shares of the Company's common stock at a price per share of $6.29 issued to the Reporting Person on August 17, 2016.
- [F2]Warrant is immediately exercisable and expires on August 17, 2019.
- [F3]These warrants were cancelled and exchanged for the right to receive 4,842 shares of common stock of the Company.